EX VIVO METHODOLOGY FOR THE EFFICACY TESTING OF ANTI-CELLULITE ACTIVES Meyer, Imkea, Marco Massironib, Gabriele Vielhaberc, Paolo Pertiled, Michele Massironid
a Symrise GmbH & Co. KG, Mühlenfeldstraße 1, 37603 Holzminden, Germany b SCoutech/Cutech srl, via San Marco 9M, 35129 Padova, Italy c Symrise SA, rue Mozart 15, 92110 Clichy, France d Cutech srl, via San Marco 9M, 35129 Padova, Italy Corresponding author: Marco Massironi, Phone: +39 049 762 8532, E-mail: email@example.com
The demand for innovative in vitro screening tools for
development process. Models targeting the epidermis and the
Therefore we developed an ex vivo excised porcine full skin
cosmetic actives is increasing. The possibility of providing
dermis are available on the market. However, there is an
model that, by including the subcutaneous tissue, is an
preclinical information in connection to both the bioavailability
unmet need for a model targeting the subcutaneous tissue,
appropriate model to gain information on the lipolytic effect of
and the long-term effect of an active ingredient is of pivotal
which is required for the proof of efficacy of anti-cellulite
an active ingredient and to assess the modulation of adipo-
importance in order to save money and speed up the
cyte size by lipolytic as well as adipogenic compounds .
MATERIALS AND METHODS
After 24 h incubation the glycerol in the surrounding medium
Adipocyte size was determined by image analysis software.
was quantified using Free Glycerol Reagent (Sigma,
The histological sections have been digitally recorded and
The pig skin organ culture model (PSOCM) was derived from
converted into a binary format (Fig. 1). A check of the binary
slaughtered animals dedicated to meat production . Skin
against the original images was performed, before the cross-
pieces of 7 mm diameter and a minimum layer (3 mm) of
sectional area of each adipocyte was calculated and
subcutis were excised from the dorsal part of a young pig.
Hydrodispersion gel with or without anti-cellulite active (i.e.
expressed as pixels . Values less than 300 pixels were
For each treatment four skin specimens have been used for
BIO1617) was applied topically to the pig skin model. The
assumed not to be adipocytes and excluded from analysis. By
the lipolysis assay and six skin specimens for the adipocyte
application has been renewed daily. After 10 days incubation
allowing the measurement of a significant number of
the skin models have been fixed in formalin, embedded in
adipocytes (i.e. 60-80) in a relatively small skin biopsy (i.e. 7
paraffin and cut with the microtome followed by staining of the
mm diameter) the model permits to obtain reliable,
histological sections with hematoxylin and eosin.
Caffeine (Acros): Anti-Cellulite active with lipolytic activity; BIO1617 (Symrise): Anti-cellulite active with triple activity, stimulator of lipolysis, inhibitor of adipogenesis as well as
lipogenesis; BIO1750 (Symrise): Anti-cellulite active without
lipolytic activity, but inhibitor of adipogenesis as well as
representations. A: Hematoxylin and eosin-stained sections of subcuta-
Hydrodispersion gel with or without anti-cellulite active (i.e.
generated binary images of A. C: Computer analysis of image B.
BIO1617) was applied topically to the pig skin model. A formulation containing caffeine served as a positive control.
for the lipolytic actives caffeine and BIO1617. On PSOCM the
activity was applied in different concentrations to evaluate the
adipocyte size was reduced after 10 days by 35% and 36%
long-term effect of the active dose-dependently. The
On PSOCM the lipolysis was stimulated by 21% and 15%
relative to placebo for 0.1% BIO1617 and 0.1% caffeine,
adipocyte size was slightly reduced by 6% and 9% relative to
relative to placebo by formulations containing 0.1% BIO1617
respectively (Figure 2). Both actives showed as a long-term
placebo by 0.1% BIO1750 and 0.2% BIO1750, respectively,
and 0.02% caffeine, respectively (data not shown).
effect a shrinkage of adipocytes inter alia due to their lipolytic
In the next step the reduction of adipocyte size was evaluated
Subsequent the anti-cellulite active BIO1750 without lipolytic
0.1% BIO1617 0.2% BIO1750 0.1% BIO1617 average area size (pixel)
* p<0,05, ** p<0,01 calculated versus vehicle
Fig. 2: Measurement of adipocytes size in ex vivo porcine skin model at day 10 (n=4) (A) applied as DMSO
Fig. 3: Alterations in adipocyte size by anti-cellulite active BIO1750 after 6 days applied in O/W formulation
solutions, (B) applied as formulations; computer image analysis after hematoxylin and eosin staining.
relative to placebo (n=6); A: Comparison of different concentrations of BIO1750; B: Comparison of placebo with 0.2% BIO1750.
Targeting the subcutaneous adipose tissue is a challenging
The presented ex vivo model is the ideal tool to study the
cosmetic active. The culture conditions enable a long-term
approach as topically applied actives have to penetrate deep
effect of topically applied finished formulations targeting
cultivation and thus an efficacy testing up to 10 days. 
into the skin. The bioavailability of actives is the major
uncertainty for the transfer of in vitro to in vivo anti-cellulite
Read-out parameters are the short-term effect of glycerol
It allows to evaluate the effect of ingredients including
release as well as the long-term effect of adipocyte size
optimization of formulations regarding bioavailability as
reduction. Thus, the model is not limited to lipolytic cosmetic
well as adaptation of effective concentrations in a
An ex vivo porcine skin model was developed that is suited
actives like caffeine. Cosmetic ingredients with adipogenic
preclinical previous toxicological
for systemic as well as topical application of anti-cellulite
and/or lipogenic efficacy result also in a reduction of
actives, including finished formulations containing the
adipocyte size when appropriately formulated.
 Massironi, M. et al., SOFW, 135 (2009) 5, 15-20
 Corino, C. et al., J Nutr, 135 (2005) 6, 1444-1450
 Novakofski, J., J Anim Sci, 82 (2004) 3, 905-915
 Chen, H.C. et al., J Lipid Res, 43 (2002) 6, 986-989
Slutrapport Revision av dokumentation, klassificering och registrering av vårdkontakter inom öppenvård vid Nacka Närsjukhus Proxima AB 25 maj 2011 Staffan Bryngelsson Emendor Consulting AB Innehållsförteckning: Två besök samma datum 2009 och 2010 . 4 6.3 DRG 970O Sjuksköterskebesök 2010 . 10 6.4 Revisorernas sammanfattade kommentarer . 11 7.
Managing Behaviour and Psychological Problems in Patients with Diagnosed or S anagement guidelines for people over 65 with diagnosed or uspected dementia in Nottingham and Nottinghamshire s Rowan Harwood, geriatrician, Nottingham University Hospitals Jonathan Waite, psychiatrist, Nottinghamshire Healthcare Trust John Lawton, pharmacist, Nottingham